Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that Vectibix((R)) (panitumumab), administered in combination
with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with F...
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
DEERFIELD, Ill., July 22, and OSAKA, Japan, July 23 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug ...
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination
of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration...
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Overview of 11 peer review publications presented in 'Future Oncology'
SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies wit...
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Combined with Clofarabine, Thiarabine Achieves High Cure Rate in a Colorectal Cancer Model
DALLAS, June 4 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that new Thiarabine preclinical efficacy data will shortly be published demo...
Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of ...
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer
NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasda...
Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer
NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination
with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...
Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination
with sunitinib (Sutent(R) - Pfizer). ...
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer -
WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administrati...
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C -
NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: IT...
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
- Results inform selection of doses, regimens to be explored in Phase 2b study -
-- Phase 2b program anticipated to begin in summer 2009 --
COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that results from a 14-day Phase 1b clinical stu...
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
TRILIPIX has now been studied in combination
with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott 's TRILIPIX(R) (fenofibric acid) delayed-...
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination
with paclitaxel and carboplatin in patients w...
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success
KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has approved new label...
Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
Dermatologist evaluates the latest laser and light sources approved for treating acne
SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- From the removal of childhood birthmarks to skin rejuvenation, laser technology has become a mainstay in dermatology. Now, dermatologists are fine-tuning t...
New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds
SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines. The disease -- which the Scleroderma Foundation esti...
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical
company focused on the discovery and development of novel antibiotics
designed to overcome the significant global problem of microbial resistance,
announces today that its most advanced injectable antibacterial, which
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression
NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...
Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination
with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma.
LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets t...
Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
Article in Gynecologic Oncology Supports Use of Fujirebio Diagnostics'
HE4 Test with CA125 for Risk Stratification of Women with Suspected Ovarian Cancer
MALVERN, Pa., Jan. 26 /PRNewswire/ -- A pivotal clinical trial published in the January 2009 issue of the journal Gynecologic Oncology ...
Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
New data demonstrates that Angiolix has similar efficacy to Avastin alone and in combination
with other chemotherapeutics, with potentially less side-effects; study validates results seen in Previous Breast Cancer Model
DALLAS, Jan. 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (O...
AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
Results Show Successful Clinical Validation of Pharmacodynamic Effect
REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain...
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today announced that it will conduct a conference call and
webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its
Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-1...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show
that patients with metastatic breast cancer who were treated previously with
an anthracycline in the adjuvant setting experienced a significant improvement
in time to disease progression (TTP) and overall response rates after
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today said that it will report top-line results in January 2009
from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in
combination with standard-of-care Pegasys(R) (peginterferon alfa-2a) and
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported the Phase I results from a randomized, multi-center,
Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide
and lenalidomide (VcDCR) in patients with previously untreated multiple
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical
company focused on the discovery and development of novel antibiotics
designed to overcome the significant global problem of microbial
resistance, announces today that its most advanced injectable
antibacterial, which comb...
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
- Ninety-six week ARTEMIS data presented at ICAAC -
BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results
presented today from a phase 3, randomized, open-label, ongoing clinical
trial showed that 79 percent of treatment-naive HIV-1 infected adults
taking PREZISTA(R) 800 mg (t...
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
NEW HAVEN, Conn., Sept. 22 /PRNewswire-FirstCall/ -- VION
PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it
had entered into an agreement with the Institut Paoli-Calmettes in
Marseille, France to conduct a multi-center Phase I/II clinical trial of
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Interim data from Phase 1b Study indicate that adecatumumab in combination
with docetaxel is safe and well tolerated and suggest a better outcome for breast cancer patients with high EpCAM expression
BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a...
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
- First of three ongoing randomized chemotherapy combination
trials to evaluate HGS-ETR1 in the treatment of specific cancers -
ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from
an ongoing randomiz...
Particle Sciences Expands Its Combination Product Capabilities
BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- Particle Sciences Inc. has
expanded its Combination
Product (drug-eluting polymers) development and
pilot production capabilities with the installation of a compounding,
extrusion and injection molding line. The core of the pilot line,
comprising a Haake...
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION
PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had
entered into an agreement with the Dutch-Belgian Cooperative Trial Group
for Hematology Oncology (the "HOVON") to conduct a clinical trial of
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
- 88% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) -
- Safety and tolerability comparable to placebo administered with Pegasys plus Copegus -
PRINCETON, N.J., Aug. 5 /PRNewswir...
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
SOMERSET, N.J., July 21 /PRNewswire-FirstCall/ -- Alfacell Corporation
(Nasdaq: ACEL ) today announced that a paper published in Molecular Cancer
Therapeutics (2008; 7(7):1871-9) reports that a combination
(ranpirnase) and the thiazolidinedione antidiabetic drug rosiglitazone
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Provides Update on Carfilzomib Development Program in Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
today announced that patient dosing has commenced in a Phase 1b clinical
trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National
Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of